Foxtons Group plc ( FXTGY) Q4 2025 Earnings Call March 5, 2026 4:00 AM EST Good morning, everyone, and thank you for joining the Foxtons' 2025 Full Year Results Presentation. I'm joined, as always, by ...
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment ...
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data ...
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at ...
AI-driven MAX platform rollout and retail enablement programs are expected to drive customer adds and client value-add in ...
Estimating things that exist is generally easy, but when it comes to estimating things that do not exist, it's more difficult. This is something physicists from Poland and the UK are well aware of. To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results